- Home
- » Tags
- » Muraglitazar
Top View
- Evaluating the Cardiovascular Safety of New Medications for Type 2
- John Bernard Buse, MD, Phd Academic Office
- Insight Into Newer Anti-Diabetic Treatment
- Oral Antidiabetic Agents-Review and Updates 2 3 Patience O
- Novel Treatments for Type 2 Diabetes
- Past and Current Perspective on New Therapeutic Targets for Type-II Diabetes
- (19) United States (12) Patent Application Publication (10) Pub
- Original Article
- PPAR in Kidney Physiology and Pathophysiology
- Role of Peroxisome Proliferator-Activated Receptors (Ppars) in Trophoblast Functions
- INFLAMMATORY BOWEL DISEASE MONITOR Commentary and Analysis on Advances in the Understanding and Management of Inflammatory Bowel Disease
- PPAR Agonists and Cardiovascular Disease in Diabetes
- Journal of Clinical and Diagnostic Research
- Improvement of Glycemic Control, Triglycerides, And
- Fibrates, Glitazones and Peroxisome Proliferator-Activated Receptors Fanny Lalloyer1,2,3,4 and Bart Staels1,2,3,4
- ( 12 ) United States Patent
- OPTIMAL THERAPY REPORT Optimal Therapy Recommendations COMPUS for the Prescribing and Use of Insulin Vol 2, Issue 7 May 2009 Analogues
- Focus on Linagliptin Annayya R
- Pleiotropic Effects of Glitazones: a Double Edge Sword?
- Approach to a Safer Insulin Sensitizer
- GLYCEMIC MANAGEMENT of TYPE 2 DIABETES (T2DM) in ADULTS Table 2: Individualization of Drug Therapy: Special Considerations
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
- Pdf Acknowledgments: None
- Wo 2010/045656 A2
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- Diseases[Version 1; Peer Review: 2 Approved]
- Safety Issues Hamper Dual PPAR Agonists: Is Partial Antagonism The
- Effect of a Dual PPAR Α/Γ Agonist on Insulin Sensitivity in Patients Of
- Lessons from the Avandia Controversy a New Paradigm for the Development of Drugs to Treat Type 2 Diabetes
- Saroglitazar, a Novel Cardiometabolic Agent for Diabetic Dyslipidemia – a Review
- Saroglitazar: India's Answer to Diabetic Dyslipidemia
- A Narrative Review of Potential Future Antidiabetic Drugs:Should We Expect More?
- How to Use Type 2 Diabetes Meds to Lower CV Disease Risk
- Saroglitazar
- Will Lecture Sot2008a
- Diabetic Dyslipidemia
- And PPAR Induces Neoangiogenesis Through a Vascular